(State or Other
Jurisdiction
of
Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
|
Written
communications pursuant to Rule 425 under the Securities
Act.
|
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act.
|
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange
Act.
|
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act.
|
Title of
Class
|
Trading
Symbol(s)
|
Exchange
Name
|
|
|
|
99.1
|
Press release
issued by TG Therapeutics, Inc., dated September 12,
2019.
|
|
TG
Therapeutics, Inc.
(Registrant)
|
|
|
|
|
|
|
Date: September 12,
2019
|
By:
|
/s/ Sean A.
Power
|
|
|
|
Sean A.
Power
|
|
|
|
Chief Financial
Officer
|
|
MBKED#/#300/2/ KFE;#()<365!H!EJX&-S,VTL5<)IPG#.L7I6A;+$ MK_O5"3S-8:ZJ89\:>F":ON%:.L-@)9BMFA[3M(V ^1*#;WHUB*-97&)99MTT MW7!#W3E,%<%"-I+(H2C#[@"!<(5CN7.#,"P!4(RR#[&:[[IM 61[ MP,AWF>Y2\ @LQBCA7D/);-V5,8R3(!Q-R[8@ M#F%R^9ZT8EP&F6GKW2[XQKN?BUN=6VQH%L,XND2A(K)=%\SJYA:[P6MH65)+ MR3]6_ZUV39CM^
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end
Document and Entity Information |
Sep. 12, 2019 |
---|---|
Document and Entity Information [Abstract] | |
Entity Central Index Key | 0001001316 |
Amendment Flag | false |
Document Type | 8-K |
Document Period End Date | Sep. 12, 2019 |
Entity Registrant Name | TG Therapeutics, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-32639 |
Entity Tax Identification Number | 36-3898269 |
Entity Address, Address Line One | 2 Gansevoort Street, 9th Floor |
Entity Address, City or Town | New York |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 10014 |
City Area Code | 212 |
Local Phone Number | 554-4484 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 |
Trading Symbol | TGTX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Ex Transition Period | false |